24 companies "besieged" AZ's original research drug!

On February 17, Shanghai Sunshine Pharmaceutical Purchasing Network issued the "Notice on Carrying out the Information Reporting of the Seventh Batch of State-Organized Centralized Drug Procurement".

After sorting out, the filling and reporting of domestically sourced drugs involves a total of 208 product regulations and 198 enterprises (according to enterprise groups)

From the perspective of industry insiders, with the normalization of centralized drug procurement, the direction of price reduction for original research drugs that have expired patents has been very clear.

18 varieties of over 1 billion were included

Up to 24 pharmaceutical companies have been evaluated

The seventh batch of domestically sourced medicines involved a total of 58 varieties and 208 product specifications

Judging from the number of companies that have over-evaluated varieties, the largest variety is omeprazole injection.

It is worth mentioning that esomeprazole enteric-coated tablets and enteric-coated capsules, which are clinically similar drugs of omeprazole sodium injection, have been included in the fourth batch of national procurement, and esomeprazole injection has been included in the The fifth batch of national mining

In addition, tenofovir alafenamide oral normal-release dosage form, clindamycin phosphate injection, cefixime oral normal-release dosage form, and nifedipine sustained-release/controlled-release dosage form have also been reviewed by more than 10 generic pharmaceutical companies

Competition situation of some original research drugs in the seventh batch of nationally sourced drugs

In terms of the structure of varieties involved in centralized procurement, the situation of the seventh batch of national procurement is most similar to that of the fifth batch.

Industry insiders predict that because injections are mainly sold in hospitals, the out-of-hospital market is almost negligible.

Domestic substitution is greatly accelerated

The normalization of centralized procurement of multinational pharmaceutical companies "do not advance or retreat"

With the continuous improvement of the quality of generic drugs in China, the continuous advancement of consistency evaluation and the normalization of centralized procurement, the market competitiveness of original drugs with expired patents has been gradually weakened, and the substitution of generic drugs has continued to accelerate

Previously, the China Medical Insurance Research Association compared the centralized procurement results for 9 drugs, including atorvastatin oral normal-release dosage form, amlodipine oral normal-release dosage form, and entecavir oral normal-release dosage form, based on incomplete statistics on the national situation.

Changes in purchase volume of unselected original research drugs

At the same time, the total annual purchases of nine drugs by their generic names increased by 23%

With the advancement of centralized procurement, the enthusiasm of foreign companies to participate has also increased

With the normalization of centralized procurement, the era of long-term high premiums for original drugs with expired patents in China is coming to an end